The role of second autografts in the management of myeloma at first relapse.
We report an analysis of the value of a second high-dose melphalan autograft, performed at relapse, on a series of newly diagnosed myeloma patients entered into the high-dose program at our center. We conclude that relapse-free survival after the first autograft is a major prognostic factor in determining outcome.
Alvares
Caroline L
CL
Davies
Faith E
FE
Horton
Clive
C
Patel
Gita
G
Powles
Ray
R
Morgan
Gareth J
GJ
D019468:Disease Management; D018572:Disease-Free Survival; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D012008:Recurrence; D016879:Salvage Therapy; D014182:Transplantation, Autologous
D008558:Melphalan